Seizures
RSSArticles
Intravenous Calcitonin Gene-Related Antibodies for the Prevention of Migraine
In a Phase 2 trial, antibodies to calcitonin gene-related peptide resulted in a significant decrease in migraine days measured from baseline to weeks 5 to 8 after one intravenous infusion of the medication, as compared to a placebo infusion. But the high-rate of placebo response (50%) warrants caution in the interpretation of the study results and requires more investigation.Cumulative Index: Volume 20, Numbers 1-12, Pages 1-96, September 2001 — August 2002
An index of Neurology Alert articles organized by topic.Increased Caloric Intake Increases the Risk of Alzheimer’s Disease
Neuropsychological Assessment Reduces False Positives in Mild Cognitive Impairment
Synopsis: Traditional comprehensive neuropsychological testing has greater reliability, sensitivity, and specificity than bedside screening tests in the accurate diagnosis of mild cognitive impairment.Role of Neurologists and Diagnostic Tests in the Management of DSP
Synopsis: Using the clinical history and simple, inexpensive laboratory tests, community-based outpatient neurologists were able to determine the cause of distal symmetric polyneuropathy in three-fourths of patients presenting with typical symptoms.Chemotherapy-Induced Neuropathy in Pediatrics
Synopsis: Chemotherapy-induced peripheral neuropathy is common in children treated for a variety of cancers, but the long-term prognosis for recovery is excellent.To Sleep, Perchance to Clear Our Beta-Amyloid
SYNOPSIS: Both animal studies and human data suggest that A-beta 42 amyloid is cleared from the brain during sleep, and that sleep deprivation may be a risk factor for the development of Alzheimer’s disease.
New Diagnostic Methods for Creutzfeldt-Jakob Disease
Synopsis: Novel noninvasive diagnostic tests for Creutzfeldt-Jakob disease (CJD; nasal brushings) and variant CJD (urinary prion proteins) are reported to be highly sensitive and specific in two recent studies.
Will New Approaches Help to Treat ALS?
Pharmacology Watch: High-Dose Rofecoxib Confirmed Prothrombotic, Study Shows
Debate over the cardiovascular effects of COX-2 inhibitors has raged for more than a year since a special communication was published in JAMA last August suggesting an increase in cardiovascular events with rofecoxib (Vioxx). Now a large retrospect, the cohort study from the Tennessee Medicaid program seems to confirm the prothrombotic effects of rofecoxib, at least in high dose.